Skip to main content
SpringerLink
Log in

Long-term adjuvant tamoxifen therapy for breast cancer

  • 12th San Antonio Breast Cancer Symposium — Plenary Lecture
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Tamoxifen (ICI46,474) is a competitive inhibitor of estrogen action which has found ubiquitous application in the treatment of breast cancer. The drug is the front line endocrine therapy for breast cancer and is the proven treatment of choice for the adjuvant therapy of postmenopausal women with node-positive disease. Tamoxifen is available for the treatment of premenopausal patients with advanced disease, and is being evaluated in clinical trials as an adjuvant therapy for premenopausal patients with either node-positive or node-negative disease. Laboratory studies demonstrate that tamoxifen is a tumoristatic agent and long-term treatment strategies (chemosuppression) should be considered to apply the antiestrogen to its maximal therapeutic advantage. Optimal therapy with tamoxifen may also be achieved by treatment strategies to lower circulating estrogen levels in the premenopausal patient.

Tamoxifen is a well tolerated drug, and long-term therapy does not appear to induce metabolic tolerance. Concerns about premature osteoporosis or cardiovascular disease appear to be unfounded because tamoxifen has an appropriate level of target site-directed estrogenic activity. Isolated reports about the growth or appearance of endometrial carcinoma during long-term adjuvant tamoxifen therapy must be balanced against the risks of withholding treatment to patients with a fatal disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Harper MJK, Walpole AL: A new derivative of triphenylethylene: Effect on implantation and mode of action in rats. J Reprod Fertil 13: 101–119, 1967

    PubMed  Google Scholar 

  2. Cole MP, Jones CTA, Todd IDH: A new antioestrogenic agent in late breast cancer: An early clinical appraisal of ICI46,474. Br J Cancer 25: 270–275, 1971

    PubMed  Google Scholar 

  3. Ward HWC: Antioestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels. Br Med J i: 13–14, 1973

    Google Scholar 

  4. O'Halloran MJ, Maddock PG: ICI 46,474 in breast cancer. J Irish Med Assoc 67: 38–39, 1974

    Google Scholar 

  5. Legha SS, Carter SK: Antiestrogens in the treatment of breast cancer. Cancer Treat Rev 3: 205–216, 1976

    PubMed  Google Scholar 

  6. Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127–205, 1984

    PubMed  Google Scholar 

  7. Legha SS: Tamoxifen in the treatment of breast cancer. Ann Int Med 109: 219–228, 1988

    PubMed  Google Scholar 

  8. Love RR: Tamoxifen therapy in primary breast cancer: Biology, efficacy and side effects. J Clin Oncol 7: 803–815, 1989

    PubMed  Google Scholar 

  9. Sawka CA, Pritchard KI, Paterson DJA, Thomson DB, Skelley WE, Myers RE, Mobbs BG, Malkin A, Meakin JW: Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast cancer. Cancer Res 46: 3152–3156, 1986

    PubMed  Google Scholar 

  10. Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahman DL, Chang MN, Bisel HF, Windschitl HE, Twito DI, Pfeifle DM: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4178–4185, 1986

  11. Buchanan RB, Blamey RW, Durrent KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4: 1326–1330, 1986

    PubMed  Google Scholar 

  12. Cancer Research Campaign Adjuvant Breast Trial Working Party: Cyclophosphamide and tamoxifen as adjuvant therapy in the management of breast cancer. Br J Cancer 57: 604–607, 1988

    Google Scholar 

  13. Fisher B, Constantino J, Redmond C, and other members of the NSABP: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 320: 479–484, 1989

    PubMed  Google Scholar 

  14. Early Breast Cancer Trialists' Collaborative Group: Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 319: 1681–1692, 1988

    Google Scholar 

  15. Jordan VC: Long-term tamoxifen therapy for breast cancer.In: DeVita VT, Hellman S, Rosenberg S (eds): Important Advances in Oncology. Lippincott, Philadelphia, pp 179–192, 1989

    Google Scholar 

  16. Jordan VC, Koerner S: Tamoxifen (ICI46,474) and the human carcinoma 8S estrogen receptor. Eur J Cancer 11: 205–206, 1975

    PubMed  Google Scholar 

  17. Skidmore JR, Walpole AL, Woodburn J: Effect of some triphenylethylenes on oestradiol bindingin vitro to macromolecules from uterus and anterior pituitary. J Endocrinol 52: 289–298, 1972

    PubMed  Google Scholar 

  18. Lippman ME, Bolan G: Oestrogen-responsive human breast cancer in long-term tissue culture. Nature (Lond) 256: 592–595, 1975

    Google Scholar 

  19. Reddel RR, Murphy LC, Sutherland RL: Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cellsin vitro. Cancer Res 43: 4618–4624, 1983

    PubMed  Google Scholar 

  20. Taylor CM, Blanchard B, Zava DT: Estrogen receptor mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res 44: 1409–1414, 1984

    PubMed  Google Scholar 

  21. Soule HD, Vazquez J, Long A, Albert S, Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409–1416, 1973

    PubMed  Google Scholar 

  22. Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, Joyce MJ: Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 38: 3352–3364, 1978

    PubMed  Google Scholar 

  23. Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaitcik S, Brenner HJ: Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 15: 659–670, 1979

    PubMed  Google Scholar 

  24. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83: 2496–2500. 1986

    PubMed  Google Scholar 

  25. Sporn MB, Todaro GJ: Autocrine secretion and malignant transformation of cells. N Engl J Med 303: 878–880, 1980

    PubMed  Google Scholar 

  26. Horwitz KB, Koseki Y, McGuire WL: Estrogen control of progesterone receptor in human breast cancer: Role of estradiol and antiestrogen. Endocrinology 103: 1742–1751, 1978

    PubMed  Google Scholar 

  27. Bates SE, Davidson NE, Vilverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME, Saloman DS: Expression of transforming growth factor α and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 2: 543–555, 1988

    PubMed  Google Scholar 

  28. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417–428, 1987

    PubMed  Google Scholar 

  29. Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK: Transforming growth factor-β: Potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 48: 3898–3904, 1988

    PubMed  Google Scholar 

  30. Robinson SP, Jordan VC: Antiestrogenic action of toremifene on hormone dependent, independent and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49: 1758–1762, 1989

    PubMed  Google Scholar 

  31. El-Sheikha Z, Klopper A, Beck JS: Treatment of menometrorrhagia with an antioestrogen: Clin Endocrinol 1: 275–282, 1972

    Google Scholar 

  32. Klopper A, Hall M: New synthetic agent for the induction of ovulation: Preliminary trial in women. Brit Med J i: 152–154, 1971

    Google Scholar 

  33. Williamson JG, Ellis JD: The induction of ovulation by tamoxifen. J Obstet Gynaecol Brit Comm 80: 844–847, 1973

    Google Scholar 

  34. Jordan VC: The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole. Breast Cancer Res Treat 11: 197–209, 1988

    Google Scholar 

  35. Huggins C, Grand LC, Brillantes P: Mammary cancer induced by a single feeding of polynuclear hydrocarbons and its suppression. Nature (Lond) 189: 204–207, 1961

    Google Scholar 

  36. Jordan VC: Antitumor activity of the antioestrogen ICI46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 5: 354, 1974

    Google Scholar 

  37. Jordan VC: Effect of tamoxifen (ICI46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12: 419–424, 1976

    PubMed  Google Scholar 

  38. Jordan VC: The antitumor effect of tamoxifen in the dimethylbenzanthracene-induced mammary carcinoma model. Proc Symposium on the Hormonal Control of Breast Cancer. Alderley Park, pp 11–17, ICI Pharmaceuticals Division PLC, Macclesfield, 1975

  39. Nicholson RI, Golder MP: The effect of synthetic antioestrogens on the growth and biochemistry of rat mammary tumours. Eur J Cancer 11: 571–579, 1975

    PubMed  Google Scholar 

  40. Jordan VC, Dowse LJ: Tamoxifen as an antitumour agent: Effect on oestrogen binding. J Endocrinol 68: 297–303, 1976

    PubMed  Google Scholar 

  41. Jordan VC, Koerner S: Tamoxifen as an antitumour agent: Role of oestradiol and prolactin. J Endocrinol 68: 305–310, 1976

    PubMed  Google Scholar 

  42. Jordan VC, Jaspan T: Tamoxifen as an antitumour agent: Oestrogen binding as a predictive test for tumour response. J Endocrinol 68: 453–460, 1976

    PubMed  Google Scholar 

  43. Jordan VC, Dix CJ, Allen KE: The effectiveness of longterm treatment in a laboratory model for adjuvant hormone therapy of breast cancer.In, Salmon SE, Jones SE (eds) Adjuvant Therapy of Cancer II. Grune and Stratton, New York, pp 19–26, 1979

    Google Scholar 

  44. Jordan VC, Allen KE: Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16: 239–251, 1980

    PubMed  Google Scholar 

  45. Jordan VC: Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen treatment as a potential adjuvant therapy. Rev Endocr Rel Cancer (Oct. Suppl): 49–55, 1978

  46. Jordan VC, Allen KE, Dix CJ: The pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 64: 745–759, 1980

    PubMed  Google Scholar 

  47. Robinson SP, Jordan VC: The reversal of the antitumor effect of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model. Cancer Res 47: 5386–5390, 1987

    PubMed  Google Scholar 

  48. Robinson SP, Mauel DA, Jordan VC: Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. Eur J Cancer Clin Oncol 24: 1817–1821, 1988

    PubMed  Google Scholar 

  49. Gullino PM, Pettigrew HM, Grantham FH: N-Nitrosomethylurea as a mammary carcinogen in rats. J Natl Cancer Inst 54: 401–414, 1975

    PubMed  Google Scholar 

  50. Wilson AJ, Tehrani F, Baum M: Adjuvant tamoxifen therapy for early breast cancer: An experimental study with reference to oestrogen and progesterone receptors. Br J Surg 69: 121–125, 1982

    PubMed  Google Scholar 

  51. Gottardis MM, Jordan VC: The antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47: 4020–4024, 1987

    PubMed  Google Scholar 

  52. Giovanella BC, Stehlin JS, Williams LJ, Lee SS, Shepard RC: Heterotransplantation of human cancers into nude mice. Cancer 42: 2269–2281, 1978

    PubMed  Google Scholar 

  53. Soule HD, McGrath CM: Estrogen proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Lett 10: 177–189, 1980

    PubMed  Google Scholar 

  54. Shafie SM, Grantham FH: Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic mice. J Natl Cancer Inst 67: 51–56, 1981

    PubMed  Google Scholar 

  55. Osborne CK, Hobbs K, Clark GM: Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic mice. Cancer Res 45: 584–590, 1985

    PubMed  Google Scholar 

  56. Gottardis MM, Robinson SP, Jordan VC: Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: A model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30: 311–314, 1988

    PubMed  Google Scholar 

  57. Jordan VC, Gottardis MM, Robinson SP, Friedl A: Immune-deficient animals to study ‘hormone-dependent’ breast and endometrial cancer. J Steroid Biochem, 1989

  58. Jordan VC, Iino Y, Langan-Fahey S, Ricchio M, Wolf DM: Reversible inhibition of oestradiol-stimulated breast cancer growth by the non-steroidal antioestrogen tamoxifen. Proc Brit Pharm Soc C127, London, Jan 3–5, 1990

  59. Jordan VC: Chemosuppression of breast cancer with tamoxifen: Laboratory evidence and future clinical investigations. Cancer Invest 6: 5–11, 1988

    Google Scholar 

  60. Osborne CK, Coronado EB, Robinson JP: Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23: 1189–1196, 1987

    PubMed  Google Scholar 

  61. Gottardis MM, Jordan VC: Development of tamoxifenstimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183–5187, 1988

    PubMed  Google Scholar 

  62. Gottardis MM, Jiang SY, Jeng MH, Jordan VC: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49: 4090–4093, 1989

    PubMed  Google Scholar 

  63. Gottardis MM, Wagner RJ, Borden EC, Jordan VC: Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growthin vivo andin vitro. Cancer Res 49: 4765–4769, 1989

    PubMed  Google Scholar 

  64. Wakeling AE, Bowler J: Steroidal pure antioestrogens. J Endocrinol 112: R7-R10, 1987

    PubMed  Google Scholar 

  65. Murray RML, Pitt P: Aminoglutethimide in tamoxifenresistant patients: The Melbourne experience. Cancer Res 42 (Suppl): 3437s-3441s, 1982

    PubMed  Google Scholar 

  66. Stoll BA: Palliation by castration or by hormone administration.In: Stoll BA (ed) Breast Cancer Management Early and Late. W. Heinemann Medical Books Ltd, London, pp 133–146, 1977

    Google Scholar 

  67. Jordan VC: Metabolites of tamoxifen in animals and man: Identification, pharmacology and significance. Breast Cancer Res Treat 2: 123–138, 1982

    PubMed  Google Scholar 

  68. Adam HK, Douglas EJ, Kemp JV: The metabolism of tamoxifen in humans. Biochem Pharmacol 27: 145–147, 1979

    Google Scholar 

  69. Jordan VC, Bain RR, Brown RR, Gosden B, Santos MA: Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res 43: 1446–1450, 1983

    PubMed  Google Scholar 

  70. Jordan VC, Collins MM, Rowsby L, Prestwich G: A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75: 305–316, 1977

    PubMed  Google Scholar 

  71. Jordan VC, Dix CJ, Naylor KE, Prestwich G, Rowsby L: Non-steroidal antioestrogens: Their biological effects and potential mechanisms of action. J Toxicol Environ Health 4: 364–390, 1978

    Google Scholar 

  72. Coezy E, Borgna JL, Rochefort H: Tamoxifen and metabolites in MCF-7 cells and correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42: 317–323, 1982

    PubMed  Google Scholar 

  73. Tormey DC, Jordan VC: Long-term tamoxifen adjuvant therapy in node-positive breast cancer: A metabolic and pilot clinical study. Breast Cancer Res Treat 4: 297–302, 1984

    PubMed  Google Scholar 

  74. Falkson HC, Gray R, Wolberg WM: Adjuvant therapy of postmenopausal women with breast cancer — an ECOG Phase III study. Abstract 67, ASCO San Francisco, May, 1989

  75. Fisher B, and other NSABP Investigators: Prolonging tamoxifen for primary breast cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project Clinical Trial. Ann Int Med 106: 649–654, 1987

    PubMed  Google Scholar 

  76. Delozier T, Julien JP, Juret P, Veyret C, Couette JE, Grai Y, Olliver JM, deRanieri E: Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial. Breast Cancer Res Treat 7: 105–110, 1986

    PubMed  Google Scholar 

  77. Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC): Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet ii: 171–175, 1987

    Google Scholar 

  78. Whitehead MI, Fraser D: Controversies concerning the safety of estrogen replacement therapy. Am J Obstet Gynecol 156: 1313–1322, 1987

    PubMed  Google Scholar 

  79. Turner RT, Wakeley GK, Hannon KS, Bell NA: Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Min Res 2: 449–456, 1987

    Google Scholar 

  80. Turner RT, Wakeley GK, Hannon KS, Bell NH: Tamoxifen inhibits osteoclast mediated resorption of trabecular bone in ovarian hormone deficient rats. Endocrinology 122: 1146–1150, 1988

    PubMed  Google Scholar 

  81. Jordan VC, Phelps E, Lingren JU: Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10: 31–35, 1987

    PubMed  Google Scholar 

  82. Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC: Bone mineral density in women with breast cancer treated for at least two years with tamoxifen. Breast Cancer Res Treat 12: 297–301, 1988

    PubMed  Google Scholar 

  83. Turken S, Siris E, Seldin E, Seldin D, Flaster E, Hyman G, Lindsay R: Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81: 1086–1088, 1989

    PubMed  Google Scholar 

  84. Rossner S, Wallgren A: Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52: 339–346, 1984

    PubMed  Google Scholar 

  85. Bertelli G, Pronzoto P, Amoroso D: Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 12: 307–310, 1988

    PubMed  Google Scholar 

  86. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, DeMets DC: Lipid and lipoprotein effects of tamoxifen therapy in postmenopausal women with node negative breast cancer. Breast Cancer Res Treat abstract 204, 1989

  87. Smith I: Adjuvant tamoxifen for early breast cancer. Br J Cancer 57: 527–528, 1988

    PubMed  Google Scholar 

  88. Jordan VC, Fritz NF, Tormey DC: Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node positive patients with breast cancer. Cancer Res 47: 624–630, 1987

    PubMed  Google Scholar 

  89. Jordan VC, Fritz NF, Tormey DC: Long-term adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin and antithrombin III. Cancer Res 47: 4517–4519, 1987

    PubMed  Google Scholar 

  90. Fex G, Adielson G, Mattson W: Oestrogen-like effects of tamoxifen on the concentration of proteins in plasma. Acta Endocrinol Copen 97: 109–113, 1981

    Google Scholar 

  91. Boccardo F, Buzzi L, Ruboyotti A, Nicolo G, Rosso R: Oestrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 38: 281–285, 1981

    PubMed  Google Scholar 

  92. Yager JD, Yager R: Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res 40: 3680–3685, 1980

    PubMed  Google Scholar 

  93. Gau T. Stuart Pharmaceuticals, A division of ICI Americas, Wilmington, Delaware. Open letter to all US medical oncologists describing the toxicological findings in rats with high dose tamoxifen treatment, 1986

  94. Fox H: Endometrial carcinogenesis and its relation to oestrogens. Path Res Pract 179: 13–19, 1984

    PubMed  Google Scholar 

  95. Swenerton KD: Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat Rep 64: 805–811, 1980

    PubMed  Google Scholar 

  96. Satyaswaroop PG, Zaino RJ, Mortel R: Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 44: 4006–4010, 1984

    PubMed  Google Scholar 

  97. Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving tamoxifen. Cancer Treat Rep 69: 237–238, 1985

    PubMed  Google Scholar 

  98. Hardell L: Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet ii: 563, 1988

    Google Scholar 

  99. Hardell L: Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri. Lancet ii: 1432, 1988

    Google Scholar 

  100. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattson A, Silversward JC, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjolmar ML: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet i: 117–120, 1989

    Google Scholar 

  101. Stewart HJ, Knight GM: Tamoxifen and the uterus and endometrium. Lancet i: 375–376, 1989

    Google Scholar 

  102. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48: 812–815, 1988

    PubMed  Google Scholar 

  103. Groom GV, Griffiths K: Effect of the antioestrogen tamoxifen on plasma levels of luteinizing hormone, folliclestimulating hormone, prolactin, oestradiol and progesterone in normal premenopausal women. J Endocrinol 70: 421–428, 1976

    PubMed  Google Scholar 

  104. Tajima C, Fukushima T: Endocrine profile in tamoxifeninduced ovulatory cycles. Fert Steril 40: 23–27, 1983

    Google Scholar 

  105. Ravdin PM, Fritz NF, Tormey DC, Jordan VC: Endocrine status of premenopausal node positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48: 1026–1029, 1988

    PubMed  Google Scholar 

  106. Nicholson RI, Walker KJ, Turkes A, Turkes AO, Dyas J, Blamey RW, Cambell FC, Robinson MRG, Griffiths K: Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118,630 in breast cancer and prostate cancer. J Steroid Biochem 20: 129–135, 1984

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Oncology, University of Wisconsin Clinical Cancer Center, 600 Highland Avenue, 53792, Madison, WI, USA

    V. Craig Jordan

Authors
  1. V. Craig Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jordan, V.C. Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res Tr 15, 125–136 (1990). https://doi.org/10.1007/BF01806350

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806350

Key words

Search

Navigation